XLO Xilio Therapeutics, Inc. - Common Stock
$9,29
Harga · Agu 19, 2026
Fundamental per Agu 12, 2026
Rentang 52M
$1–$10
94% of range
Peringkat Analis
STRONG BUY
5 analysts
Target Harga
$20
+115% upside
P/E (TTM)
-2.2
ROE
-165.5%
Margin Laba Bersih
-80.0%
XLO Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$9.29
Kapitalisasi Pasar
$42M
P/E (TTM)
-2.2
EPS (TTM)
$-4.19
Pendapatan (TTM)
$44M
Imbal Hasil Dividen
—
ROE
-165.5%
D/E Utang/Ekuitas
—
Rentang 52M
$1 – $10
XLO Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
$44M
2024-12-31
→
2025-12-31
EPS
$-4.19
2020-12-31
→
2025-12-31
Arus Kas Bebas
$-6M
2021-12-31
→
2025-12-31
Margin
-80.0%
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
XLO
Median Rekan
P/E (TTM)
-2.2
—
P/S (TTM)
1.0
100.5
P/B
1.2
1.6
Price / FCF (Harga / FCF)
-7.6
—
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
XLO
Median Rekan
Operating Margin (Margin Operasi)
-95.9%
—
Net Profit Margin (Margin Laba Bersih)
-80.0%
-1526.8%
ROA
-31.0%
-55.4%
ROE
-165.5%
-105.3%
ROIC
-119.0%
—
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
XLO
Median Rekan
Current Ratio (Rasio Lancar)
2.6
4.4
Quick Ratio (Rasio Cepat)
2.4
—
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
XLO
Median Rekan
Revenue YoY (Pendapatan YoY)
589.9%
—
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
XLO
Median Rekan
XLO Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
BELI
5 analis
- Beli Kuat 2 40,0%
- Beli 2 40,0%
- Tahan 1 20,0%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
1 analis · 2026-08-14
Rendah
$20.00
Tinggi
$20.00
Target median
$20.00
+115,3%
Target rata-rata
$20.00
+115,3%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
-0.25%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $-0.58 | $-0.59 | 0.01% |
| 31 Maret 2026 | $-0.58 | $-0.67 | 0.09% |
| 31 Des. 2025 | $0.81 | $-1.70 | 2.5% |
| 30 Sep. 2025 | $-0.08 | $-0.42 | 0.34% |
| 30 Juni 2025 | $-2.24 | $-1.13 | -1.1% |
| 31 Maret 2025 | $-2.52 | $1.34 | -3.9% |
| 31 Des. 2024 | $-2.80 | $-3.06 | 0.26% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| XLO | $3M | -0.2 | 589.9% | -80.0% | -165.5% | — |
| INMB | $41M | -0.8 | 257.1% | -91866.0% | -175.3% | — |
| EXOZ | $92M | -10.0 | — | — | -172.3% | — |
| INKT | — | -3.8 | 4.5% | -6931.8% | 63.4% | — |
| CLNN | $64M | — | -41.5% | -13086.5% | 200.2% | — |
| RNXT | — | -2.6 | 2511.6% | — | — | — |
| TCRX | — | -1.0 | 266.7% | -1256.8% | -86.6% | — |
| APLM | — | — | — | — | — | — |
| ATYR | $77M | -1.0 | -19.1% | -39009.5% | -107.8% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 13
| Metrik | Tren | 2025 | 2024 |
|---|---|---|---|
| Revenue | $44M | $6M | |
| R&D Expense | $56M | $41M | |
| SG&A Expense | $30M | $25M | |
| Operating Expenses | $86M | $67M | |
| Operating Income | $-42M | $-61M | |
| Other Non-op | $1M | $2M | |
| Pretax Income | $-35M | $-58M | |
| Income Tax | $0 | $0 | |
| Net Income | $-35M | $-58M | |
| EPS (Basic) | $-4.19 | $-15.24 | |
| EPS (Diluted) | $-4.19 | $-15.24 | |
| Shares (Basic) | 8,359,109 | 3,822,244 | |
| EBITDA | $-40M | $-59M |
Neraca 18
| Metrik | Tren | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $138M | $55M | |
| Prepaid Expense | $2M | $5M | |
| Current Assets | $145M | $60M | |
| PP&E (Net) | $4M | $4M | |
| PP&E (Gross) | $13M | $12M | |
| Accum. Depreciation | $9M | $7M | |
| Total Assets | $155M | $71M | |
| Accounts Payable | $3M | $3M | |
| Accrued Liabilities | $12M | $10M | |
| Current Liabilities | $56M | $27M | |
| Capital Leases | $6M | $7M | |
| Total Liabilities | $119M | $53M | |
| Common Stock | $0 | $5.0K | |
| Paid-in Capital | $454M | $401M | |
| Retained Earnings | $-419M | $-384M | |
| Stockholders' Equity | $35M | $18M | |
| Liabilities + Equity | $155M | $71M | |
| Shares Outstanding | 4,530,641 | 3,268,299 |
Arus Kas 10
| Metrik | Tren | 2025 | 2024 |
|---|---|---|---|
| D&A | $2M | $2M | |
| Stock-based Comp | $7M | $6M | |
| Restructuring | · | $937.0K | |
| Other Non-cash | $22M | $32M | |
| Operating Cash Flow | $-5M | $-18M | |
| CapEx | $518.0K | $36.0K | |
| Investing Cash Flow | $-518.0K | $-36.0K | |
| Financing Cash Flow | $88M | $29M | |
| Net Change in Cash | $82M | $11M | |
| Free Cash Flow | $-6M | $-18M |
Profitabilitas 7
| Metrik | Tren | 2025 | 2024 |
|---|---|---|---|
| Operating Margin | -95.9% | -955.0% | |
| Net Margin | -80.0% | -918.1% | |
| Pretax Margin | -80.0% | · | |
| EBITDA Margin | -92.4% | -929.0% | |
| ROA | -31.0% | -88.2% | |
| ROE | -165.5% | -302.0% | |
| ROIC | -119.0% | · |
Likuiditas & Solvabilitas 2
| Metrik | Tren | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 2.6 | 2.2 | |
| Quick Ratio | 2.4 | 2.0 |
Efisiensi 1
| Metrik | Tren | 2025 | 2024 |
|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 |
Tingkat Pertumbuhan 1
| Metrik | Tren | 2025 | 2024 |
|---|---|---|---|
| Revenue YoY | 589.9% | · |
Valuasi (TTM) 10
| Metrik | Tren | 2025 | 2024 |
|---|---|---|---|
| Revenue TTM | $44M | $6M | |
| Net Income TTM | $-35M | $-58M | |
| Market Cap | $3M | $44M | |
| P/E | -0.2 | -0.1 | |
| P/S | 0.1 | 6.9 | |
| P/B | 0.1 | 2.5 | |
| P / Tangible Book | 0.1 | 2.5 | |
| P / Cash Flow | -0.6 | -2.4 | |
| P / FCF | -0.5 | -2.4 | |
| Earnings Yield | -654.7% | -1595.8% |
Laporan Laba Rugi 11
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19M | $13M | $14M | $19M | $8M | $3M | $2M | $2M | $2M | |
| R&D Expense | $15M | $20M | $18M | $14M | $15M | $8M | $9M | $11M | $11M | |
| SG&A Expense | $8M | $7M | $7M | $7M | $7M | $9M | $7M | $6M | $6M | |
| Operating Expenses | $22M | $27M | $26M | $21M | $22M | $17M | $15M | $17M | $17M | |
| Operating Income | $-3M | $-14M | $-12M | $-2M | $-14M | $-14M | $-14M | $-15M | $-15M | |
| Other Non-op | $1M | $1M | $921.0K | $1M | $-1M | $586.0K | $536.0K | $742.0K | $779.0K | |
| Net Income | $-6M | $-10M | $10M | $-16M | $-16M | $-13M | $-13M | $-14M | $-14M | |
| EPS (Basic) | $-0.33 | $-0.58 | $-3.74 | $-0.11 | $-2.30 | $-2.49 | $-14.16 | $-0.22 | $-0.24 | |
| EPS (Diluted) | $-0.33 | $-0.58 | $-3.74 | $-0.11 | $-2.30 | $-2.49 | $-14.16 | $-0.22 | $-0.24 | |
| Shares (Basic) | 19,404,688 | 16,347,538 | -306,895,796 | 144,106,869 | 6,889,119 | 5,335,740 | -145,315,581 | 63,465,063 | 57,760,178 | |
| EBITDA | $-3M | · | · | $-2M | $-14M | $-13M | · | $-15M | $-15M |
Neraca 19
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $136M | $150M | $138M | $104M | $122M | $89M | $55M | $61M | $75M | |
| Prepaid Expense | $3M | $4M | $2M | $3M | $2M | $4M | $5M | $2M | $3M | |
| Current Assets | $145M | $154M | $145M | $124M | $124M | $93M | $60M | $63M | $78M | |
| PP&E (Net) | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $5M | |
| PP&E (Gross) | $13M | $13M | $13M | $12M | $12M | $12M | $12M | $12M | $12M | |
| Accum. Depreciation | $9M | $9M | $9M | $8M | $8M | $8M | $7M | $7M | $7M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | $92.0K | |
| Total Assets | $154M | $163M | $155M | $134M | $134M | $104M | $71M | $75M | $90M | |
| Accounts Payable | $2M | $1M | $3M | $2M | $4M | $2M | $3M | $972.0K | $1M | |
| Accrued Liabilities | $8M | $9M | $12M | $9M | $6M | $4M | $10M | $10M | $10M | |
| Current Liabilities | $34M | $43M | $56M | $56M | $53M | $48M | $27M | $38M | $39M | |
| Capital Leases | $5M | $5M | $6M | $6M | $6M | $7M | $7M | $7M | $8M | |
| Total Liabilities | $82M | $91M | $119M | $142M | $127M | $93M | $53M | $54M | $56M | |
| Common Stock | $1.0K | $1.0K | · | $5.0K | $5.0K | $5.0K | · | $4.0K | $4.0K | |
| Paid-in Capital | $507M | $501M | $454M | $421M | $420M | $408M | $401M | $392M | $390M | |
| Retained Earnings | $-435M | $-428M | $-419M | $-429M | $-413M | $-397M | $-384M | $-371M | $-357M | |
| Stockholders' Equity | $72M | $73M | $35M | $-8M | $7M | $11M | $18M | $21M | $33M | |
| Liabilities + Equity | $154M | $163M | $155M | $134M | $134M | $104M | $71M | $75M | $90M | |
| Shares Outstanding | 6,580,149 | 5,782,536 | 4,530,641 | 51,829,013 | 51,827,910 | 51,775,264 | 3,268,299 | 43,958,074 | 43,951,922 |
Arus Kas 10
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $331.0K | $344.0K | $323.0K | $340.0K | $381.0K | $497.0K | $376.0K | $380.0K | $445.0K | |
| Stock-based Comp | $2M | $2M | $3M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Restructuring | · | · | · | · | · | · | $0 | $-41.0K | $30.0K | |
| Other Non-cash | · | · | · | · | · | $40M | · | · | · | |
| Operating Cash Flow | $-19M | $-22M | $-2M | $-17M | $-14M | $29M | $-14M | $-14M | $20M | |
| CapEx | $19.0K | $556.0K | $95.0K | $0 | $401.0K | $22.0K | $6.0K | $9.0K | · | |
| Investing Cash Flow | $-19.0K | $-556.0K | $-95.0K | $0 | $-401.0K | $-22.0K | $-6.0K | $-9.0K | · | |
| Financing Cash Flow | $4M | $36M | $36M | $-285.0K | $47M | $5M | $8M | $-3.0K | $20M | |
| Net Change in Cash | $-14M | $13M | $34M | $-18M | $32M | $34M | $-6M | $-14M | $40M | |
| Free Cash Flow | · | · | · | · | · | $29M | · | · | · |
Profitabilitas 5
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18.7% | · | · | -10.1% | -177.7% | -472.7% | · | -652.3% | -623.8% | |
| Net Margin | -34.1% | · | · | -85.4% | -196.0% | -452.7% | · | -619.5% | -590.8% | |
| EBITDA Margin | -18.7% | · | · | -10.1% | -177.7% | -455.8% | · | -652.3% | -623.8% | |
| ROA | -4.4% | · | · | -15.6% | -14.2% | -14.2% | · | -18.4% | -15.3% | |
| ROE | -16.1% | · | · | -252.9% | -78.3% | -72.8% | · | -38.2% | -27.6% |
Likuiditas & Solvabilitas 2
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.3 | 3.6 | · | 2.2 | 2.3 | 2.0 | · | 1.7 | 2.0 | |
| Quick Ratio | 4.0 | · | · | 1.8 | 2.3 | 1.9 | · | 1.6 | 1.9 |
Efisiensi 1
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 |
Valuasi (TTM) 10
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $58M | $43M | · | $32M | $16M | · | · | · | · | |
| Net Income TTM | $-48M | $-55M | · | $-59M | $-57M | $-58M | · | $-62M | $-67M | |
| Market Cap | $63M | · | · | $44M | $35M | $37M | · | $35M | $42M | |
| P/E | -2.9 | -1.5 | · | -1.3 | -0.8 | -0.6 | · | -0.5 | -0.4 | |
| P/S | 1.1 | · | · | 1.4 | 2.3 | · | · | · | · | |
| P/B | 0.9 | · | · | -5.4 | 5.0 | 3.5 | · | 1.7 | 1.2 | |
| P / Tangible Book | 0.9 | 0.7 | · | · | 5.0 | 3.5 | · | 1.7 | 1.2 | |
| P / Cash Flow | · | · | · | · | · | 1.3 | · | · | · | |
| P / FCF | · | · | · | · | · | 1.3 | · | · | · | |
| Earnings Yield | -34.7% | -65.2% | · | -79.5% | -117.7% | -174.0% | · | -214.5% | -228.9% |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $44M | $6M | — | — | — |
| Margin Operasi % | -95.9% | -955.0% | — | — | — |
| Laba Bersih | $-35M | $-58M | $-76M | $-88M | $-76M |
| EPS Dilusian | $-4.19 | $-15.24 | $-2.78 | $-3.22 | $-13.52 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Utang / Ekuitas | — | — | 0.1 | — | — |
| Rasio Lancar | 2.6 | 2.2 | 3.0 | — | 15.8 |
| Rasio Cepat | 2.4 | 2.0 | 2.8 | — | 15.5 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-6M | $-18M | $-69M | — | $-82M |
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 3 pengaju · $8.2M total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 0 (0 vs Kuartal sebelumnya) | 0 (-35 vs Kuartal sebelumnya) | 0 (0 vs Kuartal sebelumnya) | 0 (-1 vs Kuartal sebelumnya) | 0 |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. | $6.230.727 | 650.389 | 76,24% | Saham |
| TAKEDA PHARMACEUTICAL CO LTD | $1.243.084 | 1.475.121 | 15,21% | Saham |
| VANGUARD GROUP INC | $698.605 | 1.091.570 | 8,55% | Saham |
Orang dalam perusahaan 21 orang dalam · 6 pejabat · 11 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Rene Russo | PRESIDENT AND CEO | 1 Jan. 2026 M | 325.422 | 0 | 0 | $0 |
| Christopher James Frankenfield | Chief Financial Officer | 1 Jan. 2026 M | 24.766 | 0 | 1 | $-4.499 |
| Salvatore Giovine | Chief Financial Officer | 21 Okt. 2021 A | — | 0 | 0 | $0 |
| Martin H. Huber Jr. | President of R&D and CMO | 21 Okt. 2021 A | — | 0 | 0 | $0 |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | 1 Jan. 2026 M | 33.250 | 0 | 0 | $0 |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | 1 Jan. 2026 M | 6.371 | 0 | 1 | $-1.169 |
| Akintunde Olatokumbo Bello | Direktur | 11 Juni 2026 A | — | 0 | 0 | $0 |
| Daniel J. Curran | Direktur | 11 Juni 2026 A | — | 0 | 0 | $0 |
| Yuan Xu | Direktur | 11 Juni 2026 A | — | 0 | 0 | $0 |
| Robert W. Ross | Direktur | 11 Juni 2026 A | — | 0 | 0 | $0 |
| Aoife Brennan | Direktur | 11 Juni 2026 A | — | 0 | 0 | $0 |
| Sara Bonstein | Direktur | 11 Juni 2026 A | — | 0 | 0 | $0 |
| James Samuel Shannon | Direktur | 11 Juni 2026 A | 10.000 | 1 | 0 | $43.950 |
| Cheryl R Blanchard | Direktur | 15 April 2026 A | — | 0 | 0 | $0 |
| Paul J Clancy | Direktur | 26 Okt. 2021 A | — | 0 | 0 | $0 |
| Michael Jay Ross | Direktur | 21 Okt. 2021 A | — | 0 | 0 | $0 |
| Merck KGaA | Pemilik 10% | 26 Okt. 2021 C | 680.825 | 0 | 0 | $0 |
| RiverVest Venture Fund IV, L.P. | Pemilik 10% | 26 Okt. 2021 C | 1.441.444 | 0 | 0 | $0 |
| BAY CITY CAPITAL LLC | Pemilik 10% | 26 Okt. 2021 C | 1.129.490 | 0 | 0 | $0 |
| FIL Ltd | — | 26 Okt. 2021 C | 218.705 | 0 | 0 | $0 |
| FMR LLC | — | 26 Okt. 2021 C | 4.465 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 2 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 5 Nov. 2021 | — | Pengajuan awal | — | SEC |
| SV7 Impact Medicine Fund LP, SV7 (IMF) GP LLP | 3 Nov. 2021 | — | Pengajuan awal | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 3 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.